Bone Marrow & Stem Cell Transplant

FBEM conditioning in ALL alloHSCT yielded 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or chronic graft-vs-host disease.

A first-in-class allogeneic regulatory T-cell therapy advances into multicenter phase 1b/2a trial; trial start expected second half of 2026.

Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.

In the ARES trial, MaaT013 led to improvement in refractory lower GI chronic GVHD, a key unmet need in patients receiving hematopoietic cell transplant.

The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.

An ongoing trial could establish new standard of care for chronic graft-vs-host disease.

Amandeep Salhotra, MD, discusses a retrospective observational analysis comparing Orca-T to standard graft with posttransplant cyclophosphamide.

The ACCESS study of post-transplant cyclophosphamide in stem cell transplant showed that even 6/8 and 5/8 HLA matches can be considered as donors.

Longer follow-up of patients receiving a modern prophylactic regimen shows positive outcomes for preventing chronic GVHD and relapse after stem cell transplant.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

Phase 2 interim safety data presented at the EBMT 2026 Annual Meeting suggest no additive toxicity with the novel combination chronic GVHD regimen.

Adding itacitinib to posttransplant cyclophosphamide and tacrolimus proved safe and well tolerated, with low GVHD rates and no nonrelapse mortality.

ABC trial interim results demonstrate effective, short-duration prophylaxis without conventional immunosuppressants and with dose-reduced cyclophosphamide.

Most patients with heavily pretreated chronic GVHD experienced clinical benefit with axatilimab, with the majority continuing treatment after approval.

Post-transplant gilteritinib maintenance may boost survival and reduce relapse in relapsed FLT3-mutated AML, though larger trials are still needed.

Phase 3 results show that fecal microbiotherapy achieved a 62% GI response rate and a 54% 1-year survival in patients who had failed both corticosteroids and ruxolitinib.

Fifty patients are enrolled to receive EBX-102-02 or placebo to address gut microbiome disruption associated with allogeneic hematopoietic cell transplant.

A validated analysis of nearly 22,000 patients receiving allogeneic hematopoietic cell transplant led to development of a risk calculator for acute graft-vs-host disease.

A trial found that off-the-shelf TRX103 Tr1 cells were safe to use after a mismatched donor stem cell transplant, showing engraftment, dose-dependent expansion, and persistence.

A phase 2 trial of acalabrutinib led to favorable response rates and tolerability in steroid-refractory chronic GVHD.